Contribute Try STAT+ Today

As the debate over prescription drug costs accelerates, a new report shows two pharmacy benefit managers reaped more than $223 million by working on behalf of Ohio Medicaid plans during a recent 12-month period. And the findings are likely to intensify scrutiny of the roles these companies play in shaping pharmaceutical costs nationwide.

From April 2017 through March 2018, CVS Caremark (CVS) and OptumRx billed $2.55 billion to a handful of managed care plans that administer Medicaid plans for Ohio residents. At the same time, the pharmacy benefit managers spent $2.3 billion for prescription medicines and services performed by pharmacies. This amounted to an 8.8 percent gain, or spread, of $223 million from a key profit center, according to the report.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy